Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611001008910
Ethics application status
Approved
Date submitted
17/09/2011
Date registered
20/09/2011
Date last updated
20/09/2019
Date data sharing statement initially provided
20/09/2019
Date results provided
20/09/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase II clinical trial to assess the safety and tolerability of PBT2 and its effect on amyloid levels in the brains of patients with prodromal or mild Alzheimer's disease.
Scientific title
A Randomised, Double-Blind, Placebo Controlled Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease.
Secondary ID [1] 262995 0
Nil
Universal Trial Number (UTN)
U1111-1124-2486
Trial acronym
PBT2-204 / IMAGINE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prodromal Alzheimer's disease or mild Alzheimer's disease 270699 0
Condition category
Condition code
Mental Health 270873 270873 0 0
Other mental health disorders
Neurological 271010 271010 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
PBT2 is supplied as 250mg immediate-release capsules. The dose for this study is 250mg / day ie. one capsule is to be taken orally, once a day for 52 weeks duration.
Intervention code [1] 269318 0
Treatment: Drugs
Comparator / control treatment
Placebo is supplied as identical looking, immediate-release capsules. One capsule is to be taken orally, once a day for 52 weeks duration.
Control group
Placebo

Outcomes
Primary outcome [1] 279555 0
To evaluate the effect of PBT2 compared to placebo on brain amyloid levels after 52 weeks of treatment as measured by Carbon 11-Pittsburgh Imaging Compound-B (PiB) Positron Emission Tomography (PET) imaging.
Timepoint [1] 279555 0
Baseline, 26 and 52 weeks after commencement of treatment with PBT2/placebo
Secondary outcome [1] 287893 0
To evaluate the safety and tolerability of PBT2 compared to placebo as measured by capture of vital signs, physical examination, neurological examination, ECG, eye examination, blood haematology and biochemistry, urinalysis and recording of adverse events.
From previous clinical trials, the most commonly reported side effects that were possibly related to PBT2 were fatigue (tiredness), headache, dizziness, nasopharyngitis (swollen blocked nose), and somnolence (drowsiness). Less common side-effects possibly related to PBT2 were diarrhoea, back pain, nausea and pharyngolaryngeal (throat) pain. It is possible that a rare side effect may be dissociation (a feeling of disconnecting from one's thoughts, feelings, memories or self).
Timepoint [1] 287893 0
Baseline, 4, 8, 13, 19, 26, 33, 39, 45 and 52 weeks after commencement of treatment with PBT2/placebo and 4 weeks after cessation of treatment with PBT2/placebo
Secondary outcome [2] 287894 0
To evaluate the effect of PBT2 compared to placebo on brain metabolic activity after 52 weeks as measured by Fluorine 18 labelled Fluorodeoxyglucose (FDG) PET imaging.
Timepoint [2] 287894 0
Baseline and 52 weeks after commencement of of treatment withPBT2/placebo
Secondary outcome [3] 287895 0
To evaluate the effect of PBT2 compared to placebo on brain volumes after 52 weeks as assessed by Magnetic Resonance Imaging (MRI) to measure the cortical grey matter volume, hippocampal volume and ventricular volume.
Timepoint [3] 287895 0
Baseline and 52 weeks after commencement of of treatment withPBT2/placebo
Secondary outcome [4] 287896 0
To evaluate the effect of PBT2 compared to placebo on cognition after 52 weeks as measured by a Neuropsychological Test Battery (NTB) questionnaires and the Mini-mental State Examination (MMSE) questionnaire.
Timepoint [4] 287896 0
Baseline, 13, 26, 39 and 52 weeks after commencement of treatment with PBT2/placebo
Secondary outcome [5] 287897 0
To evaluate the effect of PBT2 compared to placebo on functional ability after 52 weeks as measured by the Alzheimer's disease Cooperative Study-Activities of Daily Living-23 (ADCS-ADL-23) questionnaire
Timepoint [5] 287897 0
Baseline and 52 weeks after commencement of treatment with PBT2/placebo

Eligibility
Key inclusion criteria
1. Prodromal Alzheimer's disease or mild Alzheimer's disease
2. 11C-PiB-PET positive (SUVR>1.7)
3. MMSE >or= 20
Minimum age
55 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Allergy to PBT2 or its excipients (microcrystalline cellulose, pregelatinised starch, colloidal silicon dioxide, povidone K29/32 and sodium stearyl fumurate).
2. Have other primary neurodegenerative disorders associated with dementia (e.g. Parkinson’s Disease Dementia, Fronto-temporal Lobe Dementia, Lewy Body Dementia or Vascular Dementia)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Eligible participants will be entered on to the trial in sequence as their eligibility is confirmed. Participants will be allocated a unique Randomisation ID Number. Each participant will receive only PBT2 or placebo, with treatment assigned according to a Randomisation Schedule prepared by an independent statistician.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The Randomisation Schedule is generated by an independent statistician at a ratio of 2:1 ie. 2/3 participants will receive 250mg PBT2 and 1/3 participants will receive matching placebo.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
17/10/2011
Actual
2/03/2012
Date of last participant enrolment
Anticipated
Actual
28/11/2012
Date of last data collection
Anticipated
Actual
6/01/2014
Sample size
Target
42
Accrual to date
Final
42
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 498 0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg West
Recruitment hospital [2] 499 0
Caulfield Hospital - Caulfield
Recruitment hospital [3] 500 0
Delmont Private Hospital - Glen Iris
Recruitment hospital [4] 501 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [5] 502 0
Barwon Health - Geelong Hospital campus - Geelong
Recruitment postcode(s) [1] 4456 0
3081
Recruitment postcode(s) [2] 4457 0
3162
Recruitment postcode(s) [3] 5419 0
3146
Recruitment postcode(s) [4] 6242 0
3050 - Royal Melbourne Hospital
Recruitment postcode(s) [5] 6243 0
3220 - Geelong

Funding & Sponsors
Funding source category [1] 269806 0
Charities/Societies/Foundations
Name [1] 269806 0
Alzheimer's Drug Discovery Foundation (ADDF)
Country [1] 269806 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Alterity Therapeutics
Address
Level 3, 460 Bourke St, Melbourne, 3000, Victoria
Country
Australia
Secondary sponsor category [1] 268841 0
None
Name [1] 268841 0
Address [1] 268841 0
Country [1] 268841 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 271769 0
Austin Health Human Research Ethics Committee
Ethics committee address [1] 271769 0
Ethics committee country [1] 271769 0
Australia
Date submitted for ethics approval [1] 271769 0
17/08/2011
Approval date [1] 271769 0
17/11/2011
Ethics approval number [1] 271769 0
HREC/11/Austin/42

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33105 0
A/Prof Associate Professor Michael Woodward
Address 33105 0
Medical & Cognitive Research Unit
Heidelberg Repatriation Hospital
300 Waterdale Road
Heidelberg West, VIC 3081
Country 33105 0
Australia
Phone 33105 0
+61 (0)3 9496 2852
Fax 33105 0
Email 33105 0
[email protected]
Contact person for public queries
Name 16352 0
Cynthia Wong
Address 16352 0
Alterity Therapeutics, 39899 Balentine Drive, Suite 360, Newark, CA 94560,
Country 16352 0
United States of America
Phone 16352 0
+16503002141
Fax 16352 0
N/A
Email 16352 0
[email protected]
Contact person for scientific queries
Name 7280 0
David Stamler
Address 7280 0
Alterity Therapeutics, 39899 Balentine Drive, Suite 360, Newark, CA 94560,
Country 7280 0
United States of America
Phone 7280 0
+16503002141
Fax 7280 0
N/A
Email 7280 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseA randomized, exploratory molecular imaging study targeting amyloid beta with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.2017https://dx.doi.org/10.1016/j.trci.2017.10.001
Dimensions AIRedox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease2021https://doi.org/10.3390/ijms22147697
EmbaseEffects of three kinds of anti-amyloid-beta drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: A systematic review and meta-analysis of phase II/III clinical trials in Alzheimer's disease.2023https://dx.doi.org/10.1016/j.arr.2023.101959
N.B. These documents automatically identified may not have been verified by the study sponsor.